{"id":154235,"date":"2026-11-17T15:51:04","date_gmt":"2026-11-17T06:51:04","guid":{"rendered":"https:\/\/japanir.jp\/en\/ir\/4882-20261117-01_wp_financial_summary\/"},"modified":"2026-11-17T15:51:04","modified_gmt":"2026-11-17T06:51:04","slug":"4882-20261117-01_wp_financial_summary","status":"publish","type":"ir_release","link":"https:\/\/japanir.jp\/en\/company\/company-4882\/ir\/4882-20261117-01_wp_financial_summary\/","title":{"rendered":"Fiscal Year Ending March 2027 Q2 Financial Results Presentation"},"content":{"rendered":"<p>Disclosed the financial overview and financial condition for FY ending March 2027 Q2. Revenue declined year-over-year and net income posted a loss. Explained profit and loss fluctuations reflecting R&#038;D expenditures and grant impacts. Also presented pipeline progress and growth strategy going forward.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4882","jir_company_name":"Perseus Proteomics Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-17","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4882-20261117-01.pdf","jir_short_summary":"Disclosed the financial overview and financial condition for FY ending March 2027 Q2. Revenue declined year-over-year and net income posted a loss. Explained profit and loss fluctuations reflecting R&D expenditures and grant impacts. Also presented pipeline progress and growth strategy going forward.","jir_summary":"### Overview of Results\nIn the FY ending March 2027 Q2 results, revenue decreased year-over-year, and net income was in deficit due to research and development expenditures and the impact of grants. Financially, cash was reported at an ending balance of 1,420 million yen and the equity ratio was 62.7%. Derivation activities and clinical development progress centered on PPMX-T003\/T002 were also disclosed, indicating completion of non-GLP toxicity tests and ongoing clinical trial progress.\n\n### Outlook and Strategy\nAs a growth strategy, we will strengthen integration of antibody acquisition technologies and AI-driven drug discovery to expand the drug discovery pipeline and enter new areas. Emphasis will be placed on expanding collaborative research, accelerating derivation and clinical development using phage libraries, and progress of investigator-initiated trials. External support developments such as AMPED will also be closely monitored.","jir_financial_highlights":"Revenue: Unknown (Year-over-Year decline)\nGross Profit: Unknown (Unknown)\nOperating Income: -399 million yen (Year-over-Year change unknown)\nOrdinary Income: -345 million yen (Year-over-Year change unknown)\nNet Income Attributable to Owners of Parent: -379 million yen (Year-over-Year change unknown)\nCash and Cash Equivalents: Includes translation differences on cash and cash equivalents (Ending balance 1,420 million yen)","jir_category":"","jir_hashtags":"#NoShareBuyback, #Earnings, #AntibodyDrugDiscovery, #IRResults","jir_key_figures":"Revenue: Unknown\nNet Income Attributable to Owners of Parent: -379 million yen\nCash and Cash Equivalents, Ending Balance: 1,420 million yen","jir_meta_title":"Perseus Proteomics Inc. Q2 FY2027 Financial Summary | IR","jir_meta_description":"Perseus Proteomics Inc. Q2 FY2027 financial summary: revenue, net income, cash balance, progress of PPMX-T003\/T002 derivation and clinical development, and growth strategy explained.","jir_og_title":"Perseus Proteomics Inc. | FY2027 Q2 Financial Summary","jir_og_description":"Concise summary of FY2027 Q2 financial results, R&D progress, and future growth strategy.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[]","ir_related_company":60609,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-154235","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Fiscal Year Ending March 2027 Q2 Financial Results Presentation - Japan IR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/japanir.jp\/en\/company\/company-4882\/ir\/4882-20261117-01_wp_financial_summary\/\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4882\/ir\/4882-20261117-01_wp_financial_summary\/\",\"url\":\"https:\/\/japanir.jp\/en\/company\/company-4882\/ir\/4882-20261117-01_wp_financial_summary\/\",\"name\":\"Fiscal Year Ending March 2027 Q2 Financial Results Presentation - Japan IR\",\"isPartOf\":{\"@id\":\"https:\/\/japanir.jp\/en\/#website\"},\"datePublished\":\"2026-11-17T06:51:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4882\/ir\/4882-20261117-01_wp_financial_summary\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/japanir.jp\/en\/company\/company-4882\/ir\/4882-20261117-01_wp_financial_summary\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4882\/ir\/4882-20261117-01_wp_financial_summary\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/japanir.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fiscal Year Ending March 2027 Q2 Financial Results Presentation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/japanir.jp\/en\/#website\",\"url\":\"https:\/\/japanir.jp\/en\/\",\"name\":\"Japan IR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/japanir.jp\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Fiscal Year Ending March 2027 Q2 Financial Results Presentation - Japan IR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/japanir.jp\/en\/company\/company-4882\/ir\/4882-20261117-01_wp_financial_summary\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/japanir.jp\/en\/company\/company-4882\/ir\/4882-20261117-01_wp_financial_summary\/","url":"https:\/\/japanir.jp\/en\/company\/company-4882\/ir\/4882-20261117-01_wp_financial_summary\/","name":"Fiscal Year Ending March 2027 Q2 Financial Results Presentation - Japan IR","isPartOf":{"@id":"https:\/\/japanir.jp\/en\/#website"},"datePublished":"2026-11-17T06:51:04+00:00","breadcrumb":{"@id":"https:\/\/japanir.jp\/en\/company\/company-4882\/ir\/4882-20261117-01_wp_financial_summary\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/japanir.jp\/en\/company\/company-4882\/ir\/4882-20261117-01_wp_financial_summary\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/japanir.jp\/en\/company\/company-4882\/ir\/4882-20261117-01_wp_financial_summary\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/japanir.jp\/en\/"},{"@type":"ListItem","position":2,"name":"Fiscal Year Ending March 2027 Q2 Financial Results Presentation"}]},{"@type":"WebSite","@id":"https:\/\/japanir.jp\/en\/#website","url":"https:\/\/japanir.jp\/en\/","name":"Japan IR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/japanir.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"related_company_data":{"id":"60609","title":"PERSEUS PROTEOMICS INC","ticker":"4882"},"_links":{"self":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/154235","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release"}],"about":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/types\/ir_release"}],"replies":[{"embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/comments?post=154235"}],"version-history":[{"count":0,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/154235\/revisions"}],"wp:attachment":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/media?parent=154235"}],"wp:term":[{"taxonomy":"sector","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/sector?post=154235"},{"taxonomy":"importance","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/importance?post=154235"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}